Assessing the Complexities of Utilizing BH3 Mimetics for a Senolytic Strategy in Combination with Ionizing Radiation

Area of Science:

• Oncology
• Radiation Oncology
• Cellular Senescence

Background:

• Radiation-induced senescence (RIS) is a mechanism of tumor cell survival post-irradiation.
• Therapy-induced senescence (TIS) can promote tumor recovery, recurrence, and adverse radiation effects via the senescence-associated secretory phenotype (SASP).
• Senolytic agents are being investigated to eliminate senescent tumor cells.

Purpose of the Study:

• To review the literature on the efficacy of senolytic agents, specifically ABT-263, in combination with radiation therapy.
• To assess the potential of senolytic agents in overcoming treatment resistance and protecting normal tissues.
• To explore alternative senolytic agents like ABT-199 due to the toxicity of ABT-263.

Main Methods:

• Literature review of preclinical studies in cell culture and tumor-bearing animal models.
• Analysis of studies investigating senolytic agents (ABT-263, ABT-199) in combination with various radiation regimens.
• Evaluation of drug action timing relative to irradiation and senescent cell burden.

Main Results:

• Preclinical data suggest ABT-263 enhances radiosensitivity in cell culture models, with or without prior senescence induction.
• In vivo studies show efficacy but highlight tumor cell recovery potential after drug withdrawal.
• ABT-263 exhibits significant toxicities (thrombocytopenia, neutropenia), limiting its clinical application.
• ABT-199 shows potential for improved radiosensitivity, suggesting Bcl-xL targeting may not be essential.
• Senolytic agents may protect normal tissues from radiation damage.

Conclusions:

• Senolytic agents, particularly ABT-263, show promise in preclinical models for enhancing radiation therapy efficacy against tumors.
• Drug toxicity and tumor cell recovery remain significant challenges for clinical translation.
• Alternative agents like ABT-199 and the potential protective effects on normal tissues warrant further investigation.
• Senolytics may offer a novel strategy to mitigate radiation-induced normal tissue toxicity.